Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of intranasal ERC-872601 in healthy adults and elderly participants
jRCT2031260462Phase 1Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in influenza comparing ERC-872601 with Placebo (2 arms). Primary endpoints: Incidence of adverse events, Incidence of adverse reactions and 7 more. Started Sep 2026; status: recruiting.
02
Drugs
ERC-872601
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2031260462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260462.